Brw Stable Return Fund (ANTH)

Overview

Anthera Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to developing and bringing to market therapies for patients with significant unmet medical needs. The company, founded in 2004, is headquartered in Houston, Texas. Anthera specializes in advancing novel treatments through clinical development, particularly focusing on autoimmune and digestive diseases. With a strong commitment to patient health, Anthera leverages strategic partnerships with industry leaders such as Amgen, Inc., and Eli Lilly and Company to enhance its product pipeline and technological capabilities.

Products and Services

• Sollpura

  A non-porcine investigational pancreatic enzyme replacement therapy, Sollpura is designed to treat patients suffering from exocrine pancreatic insufficiency. Currently in Phase III clinical trials, Sollpura represents Anthera's commitment to addressing critical gaps in care for patients with digestive disorders. By offering a potentially innovative treatment option, Anthera aims to significantly improve the quality of life for individuals with this challenging condition.

• Blisibimod

  In the realm of autoimmune diseases, Anthera is developing Blisibimod, a novel candidate in Phase II clinical trials targeting B-cell mediated autoimmune diseases. This includes conditions such as immunoglobulin A nephropathy (IgA nephropathy), where current treatment options are limited. Blisibimod's mechanism of action involves modulating the B-cell activity, offering hope for patients who are battling these immune system-related disorders.